Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian, Beijing 100142, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian, Beijing 100142, China.
Eur J Radiol. 2022 Oct;155:110507. doi: 10.1016/j.ejrad.2022.110507. Epub 2022 Sep 5.
We aimed to evaluate [Ga]Ga-DOTA-FAPI-04 versus [F]FDG PET/CT in the application of fibroblastic tumors.
Twenty participants with 6 subtypes of fibroblastic tumors prospectively underwent F-FDG and [Ga]Ga-DOTA-FAPI-04 PET/CT examinations to evaluate the lesions. PET/CT findings were confirmed by surgical pathology of fifteen participants, puncture biopsy of two participants, or imaging follow-up of three participants. Two independent sample t tests were used to compare the uptake of [F]FDG vs [Ga]Ga-DOTA-FAPI-04 in primary, recurrent and metastatic lesions. One-way ANOVA was used to compare the uptake of [F]FDG or [Ga]Ga-DOTA-FAPI-04 among primary, recurrent, and metastatic lesions. The uptake of [Ga]Ga-DOTA-FAPI-04 vs [F]FDG in different histopathological lesions was compared by two independent sample t tests.
Twenty participants were confirmed to have 38 lesions. Although there was no significant difference in the detection of lesions between [Ga]Ga-DOTA-FAPI-04 and [F]FDG PET/CT (38 vs 36, p = 0.493), the uptake of [Ga]Ga-DOTA-FAPI-04 in lesions was significantly higher than that of [F]FDG (p < 0.001), including primary (p < 0.001), recurrent (p = 0.018) and metastatic (p < 0.001) lesions. The SUVmax of [Ga]Ga-DOTA-FAPI-04 in primary and recurrent lesions was higher than that in metastasis (p = 0.034 and p = 0.015, respectively). The SUVmax of [Ga]Ga-DOTA-FAPI-04 in primary and recurrent malignant lesions was significantly higher than that of the intermediate (p < 0.001). The SUVmax of [Ga]Ga-DOTA-FAPI-04 in one participant of recurrent SFT with 5 lesions was significantly lower after treatment than before treatment (p = 0.016).
[Ga]Ga-DOTA-FAPI-04 outperformed [F]FDG PET/CT in displaying the primary, recurrent and metastatic lesions of fibroblastic tumors.
评估[Ga]Ga-DOTA-FAPI-04 与[F]FDG PET/CT 在纤维母细胞瘤中的应用。
20 名参与者的 6 种纤维母细胞瘤亚型前瞻性接受了 F-FDG 和[Ga]Ga-DOTA-FAPI-04 PET/CT 检查以评估病变。15 名参与者的手术病理、2 名参与者的穿刺活检和 3 名参与者的影像学随访结果证实了 PET/CT 检查结果。采用两独立样本 t 检验比较原发、复发和转移病灶中[F]FDG 与[Ga]Ga-DOTA-FAPI-04 的摄取。采用单因素方差分析比较原发、复发和转移病灶中[F]FDG 或[Ga]Ga-DOTA-FAPI-04 的摄取。采用两独立样本 t 检验比较不同组织病理学病变中[Ga]Ga-DOTA-FAPI-04 与[F]FDG 的摄取。
20 名参与者共确诊 38 个病灶。尽管[Ga]Ga-DOTA-FAPI-04 与[F]FDG PET/CT 对病灶的检出率无显著差异（38 与 36，p=0.493），但病灶中[Ga]Ga-DOTA-FAPI-04 的摄取量明显高于[F]FDG（p<0.001），包括原发（p<0.001）、复发（p=0.018）和转移病灶（p<0.001）。原发和复发病灶[Ga]Ga-DOTA-FAPI-04 的 SUVmax 高于转移病灶（p=0.034 和 p=0.015）。原发和复发恶性病变中[Ga]Ga-DOTA-FAPI-04 的 SUVmax 明显高于中间型病变（p<0.001）。1 例复发性 SFT 患者的 5 个病灶经治疗后与治疗前相比，[Ga]Ga-DOTA-FAPI-04 的 SUVmax 明显降低（p=0.016）。
[Ga]Ga-DOTA-FAPI-04 在显示纤维母细胞瘤的原发、复发和转移病灶方面优于[F]FDG PET/CT。
